Hepatitis delta is a rare liver disease so severe and so long neglected that until May 2026, no drug had ever been FDA-approved to treat it in the United States. That changed on May 22, 2026, when Gilead’s Hepcludex won accelerated approval. Now Vir Biotechnology wants to change it again, this time more decisively.
Why This Stock Now
Sunday morning, before most investors had finished their coffee, Vir Biotechnology (VIR) dropped the data everyone had been waiting for. The ECLIPSE 1 trial showed that 44% of participants achieved undetectable hepatitis delta virus levels plus ALT normalization after 48 weeks, significantly outperforming the control group. The more granular picture is striking: 79% of treated patients had virus levels too low for tests to detect, while that 44% figure reflects the stricter combined endpoint requiring both undetectable virus and normalized ALT, a liver enzyme used to assess liver injury.
The Business
Chronic hepatitis delta is estimated to affect around 15 to 20 million people globally, virtually all of them already living with hepatitis B. The disease progresses faster than any other form of viral hepatitis toward cirrhosis, liver failure, and death. Until recently, clinicians relied on off-label interferon-based regimens with limited efficacy.
Vir’s combination works differently. The ECLIPSE program evaluates tobevibart in combination with elebsiran, covering three randomized, controlled trials in different patient settings. The monthly subcutaneous regimen is a meaningful practical advantage over daily injection-based alternatives. Safety data from ECLIPSE 1 reinforced that edge: the combination met the primary endpoint and was well tolerated, with all patients completing 48 weeks of treatment.
Why Wall Street Is Paying Attention
The trial result is half the story. The balance sheet is the other half. Vir ended the third quarter of 2026 with about $901 million in cash, cash equivalents and investments and said it expects its cash to fund operations into the second half of 2028, excluding the $90 million Gilead upfront. That Gilead collaboration, which closed on October 9, 2026, is for Vir’s oncology platform, not its hepatitis program, but it carries real validation weight: Vir received $90 million in cash consideration (a $65 million upfront payment plus a $25 million equity investment), and said it is eligible for up to $45 million in near-term preclinical milestones and up to $1.74 billion in further development, regulatory, and commercial milestones. A company that Gilead will write that kind of check for does not need to scramble for capital ahead of a regulatory filing.
Also worth noting: in a separate, exploratory analysis in Vir’s Phase 2 SOLSTICE study, 10 patients who stopped treatment after sustained suppression all remained virus-suppressed through 12 weeks of follow-up, and seven remained virus-suppressed at 24 weeks, though the small sample and limited follow-up do not establish a lasting cure. Early durability signals in a disease this severe matter to prescribers and to payers.
What’s Driving the Opportunity
Results were presented at AASLD’s Liver Meeting 2026 in Denver, with additional pivotal trial results expected in the first quarter of 2027, supporting a planned FDA submission in mid-2027. ECLIPSE 2 and ECLIPSE 3 data, covering patients who failed bulevirtide and international markets where it is established, will round out the global filing package. A successful FDA submission in mid-2027 would put Vir’s combination on the market before the end of that year, depending on review speed.
The accelerated approval standard Gilead cleared with Hepcludex used a 48-week combined response rate of 48% in its pivotal study. Vir’s 44% combined response in ECLIPSE 1 sits just below that figure, though Vir’s undetectable-virus rate of 79% at Week 48 is far higher than Hepcludex’s undetectable-virus rate reported at Week 48. The comparison is not perfectly apples to apples, but regulators will scrutinize it.
What Could Go Wrong
The competitive clock is ticking loudly. The FDA approved bulevirtide as Hepcludex, the first FDA-approved treatment for chronic hepatitis delta virus infection, on May 22, 2026. Gilead has first-mover advantage, physician relationships, and a commercial infrastructure Vir does not yet have. That matters in a rare disease market where diagnosis rates are already low.
Mirum Pharmaceuticals adds a second front. In September 2026, Mirum announced that the Phase 3 AZURE-1 study of brelovitug achieved the primary combined endpoint at Week 24 in both dose arms. At Week 24, 56% of patients on brelovitug 300mg weekly achieved the combined endpoint of virologic response and ALT normalization, and Mirum has said it plans to submit a BLA to the FDA in the first half of 2027. That filing could land before Vir’s. Brelovitug carries FDA Breakthrough Therapy designation, which can help speed development and review.
Vir’s combined response rate of 44% at 48 weeks, while clinically meaningful, trails brelovitug’s 56% at 24 weeks on a surface reading. The patient populations and endpoint timing differ, so direct comparison is imprecise, but investors bidding up VIR today should not assume the efficacy question is closed. Vir’s third quarter 2026 report also underscored that this is still a cash-burning business, with a net loss of $96.3 million in the third quarter of 2026.
The Bottom Line
Vir cleared the bar it needed to clear. ECLIPSE 1 is a genuine pivotal success: clean safety, strong virologic suppression, and a p-value below 0.0001 against a zero-response control arm. The company has the cash to reach the FDA without diluting shareholders, and the Gilead relationship adds credibility the market had not fully priced in. What Vir does not yet have is a drug on pharmacy shelves. Hepcludex is there now, and brelovitug may beat Vir’s combination to approval. The stock is worth owning for investors who can tolerate a 12-to-18-month wait for regulatory clarity, but the thesis depends on two more trial readouts arriving cleanly in early 2027. Today’s conference call at 8:30am ET will tell investors whether management’s confidence in those remaining data matches what ECLIPSE 1 just delivered.
